Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Allergan : Receives Refusal to File Letter from FDA for Vraylar® cariprazine Supplemental New Drug Application sNDA for the Treatment of Negative...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:46pm CEST

Allergan Receives Refusal to File Letter from FDA for Vraylar® cariprazine Supplemental New Drug Application sNDA for the Treatment of Negative Symptoms in Schizophrenia

By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Allergan plc (NYSE: AGN) announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for treatment of negative symptoms associated with schizophrenia in adult patients. VRAYLAR is an oral, once daily atypical antipsychotic approved in the United States for the treatment of schizophrenia and the acute treatment of adult patients with manic or mixed episodes associated with bipolar I disorder (see also Allergan plc).

Upon its preliminary review, FDA determined that the sNDA for treatment of negative symptoms was not sufficiently complete to permit a substantive review.

"We are disappointed with the FDA decision on our submission. We will request a meeting with FDA to discuss and determine our next steps. Vraylar is an important treatment option for patients suffering from bipolar I disorder and schizophrenia. We remain committed to our mental health program and to cariprazine and its potential as a treatment option for patients suffering from negative symptoms associated with schizophrenia," said David Nicholson Ph.D., Chief Research & Development Officer, Allergan.

Schizophrenia is a chronic and disabling disorder that includes positive symptoms (i.e. hallucinations, delusions and thought disorders) and negative symptoms (i.e. loss of motivation and social withdrawal). These symptoms are strongly associated with long term morbidity, poor psychosocial functioning and considerable social and economic costs.

Cariprazine is approved in Europe for the treatment of schizophrenia. The approval includes data from the 460-patient negative symptoms study which was conducted by Gedeon Richter and published in the Lancet on February 6, 2017.

The Company will seek immediate guidance, and is in the process of planning a meeting with the FDA, to respond to the issues, and to seek clarification of what additional information will be required.

Keywords for this news article include: Psychiatry, FDA Actions, Allergan plc, Schizophrenia, Mental Health Diseases and Conditions, Government Agencies Offices and Entities.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
06/18ALLERGAN : Continues Active Board Refreshment Process
AQ
06/15UK's Indivior will fight U.S. FDA's approval for copycat drug
RE
06/15ALLERGAN : Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR I..
AQ
06/14ALLERGAN : Teams Up with a Host of Celebrities to Encourage Alzheimer's Patients..
AQ
06/14ABBOTT LABORATORIES : Allergan appoints former Abbott executive to its board
RE
06/14ALLERGAN : Continues Active Board Refreshment Process
PR
06/13ALLERGAN : Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (..
PR
06/13ALLERGAN : Lawsuit Filed Against Allergan for Defectively Packaged Taytulla&trad..
AQ
06/13ALLERGAN : Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy ..
AQ
06/12ALLERGAN : and Actress Shay Mitchell Join Forces to Inspire Women to Know Their ..
AQ
More news
News from SeekingAlpha
07:21aEVOLUS : Botox Competitor Poised For Massive Growth 
06/18SYNERGY PHARMACEUTICALS : At Last A Glimmer Of Hope? 
06/15YOUR DAILY PHARMA SCOOP : Wright Receives PMA, Allergan And Corbus Report Positi.. 
06/14Allergan ticks higher as activist investors dial up the pressure for value-bo.. 
06/14Allergan continues active board refreshment process 
Financials ($)
Sales 2018 15 289 M
EBIT 2018 7 368 M
Net income 2018 -1 127 M
Debt 2018 23 406 M
Yield 2018 1,59%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,34x
EV / Sales 2019 5,03x
Capitalization 58 224 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 206 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC5.87%58 224
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
MERCK AND COMPANY8.39%166 880